First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
MMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.
Authors
- Francisco‐Javier Gamo (ORCID: https://orcid.org/0000-0002-1854-2882)
- Stephan Chalon (ORCID: https://orcid.org/0000-0002-9306-1851)
- Benoît Bestgen (ORCID: https://orcid.org/0000-0002-2019-2113)
- Annick Janin (ORCID: https://orcid.org/0009-0004-7426-0304)
- Anthony Cahn (ORCID: https://orcid.org/0000-0002-7239-0461)
- Andrea Kuemmerle (ORCID: https://orcid.org/0000-0001-5621-2676)
- Raman Sharma (ORCID: https://orcid.org/0000-0002-5437-5743)
- Rachel A. Gibson (ORCID: https://orcid.org/0000-0002-1338-1290)
- Laura M. Sanz (ORCID: https://orcid.org/0000-0003-0796-5211)
- Denis Gossen (ORCID: https://orcid.org/0009-0005-2704-1560)
- Somasekhara R. Menakuru
- Nand Singh
- Tom Dove
- Erin Lambourne
Institutions
- Age UK (GB)
- Quotient Clinical (United Kingdom) (GB)
- Medicines for Malaria Venture (CH)
- GMV Innovating Solutions (Spain) (ES)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-02-16
- DOI
- https://doi.org/10.1002/bcp.70000
- Citations
- 1
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- Bill and Melinda Gates Foundation
- Medicines for Malaria Venture